Global Molecular Diagnostics Partnering Terms and Agreements 2015-2022

$3,495.00

Global Molecular Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2022
Number of pages
550+
Product type
Research report
Available formats
PDF document
Report edition
2
SKU
CP2102mol

The Global Molecular Diagnostics Partnering Terms and Agreements 2015-2022 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  

 

This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2015.

 

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.

 

The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 900 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Molecular Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Molecular Diagnostics dealmaking since 2015, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Molecular Diagnostics deals since 2015. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Molecular Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Molecular Diagnostics deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2015. The chapter is organized by specific Molecular Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Molecular Diagnostics partnering and dealmaking since 2015.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Molecular Diagnostics technologies and products.

 

Key benefits

 

Global Molecular Diagnostics Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:

 

  • In-depth understanding of Molecular Diagnostics deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2015
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Molecular Diagnostics Partnering Terms and Agreemets 2015-2022 is intended to provide the reader with an in-depth understanding and access to Molecular Diagnostics trends and structure of deals entered into by leading companies worldwide.

 

Molecular Diagnostics Partnering Terms and Agreements includes:

 

  • Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to Molecular Diagnostics contract documents
  • Leading Molecular Diagnostics deals by value since 2015
  • Most active Molecular Diagnostics dealmakers since 2015

 

In Global Molecular Diagnostics Partnering Terms and Agreements 2015-2022, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Molecular Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 900 Molecular Diagnostics deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Molecular Diagnostics Partnering Terms and Agreements 2015-2022 report provides the reader with the following key benefits:

 

  • In-depth understanding of Molecular Diagnostics deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Molecular Diagnostics dealmakers since 2015
  • Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Molecular Diagnostics dealmaking

 

2.1. Introduction

2.2. Molecular Diagnostics partnering over the years

2.3. Most active Molecular Diagnostics dealmakers

2.4. Molecular Diagnostics partnering by deal type

2.5. Molecular Diagnostics partnering by therapy area

2.6. Deal terms for Molecular Diagnostics partnering

2.6.1 Molecular Diagnostics partnering headline values

2.6.2 Molecular Diagnostics deal upfront payments

2.6.3 Molecular Diagnostics deal milestone payments

2.6.4 Molecular Diagnostics royalty rates

 

Chapter 3 – Leading Molecular Diagnostics deals

 

3.1. Introduction

3.2. Top Molecular Diagnostics deals by value

 

Chapter 4 – Most active Molecular Diagnostics dealmakers

 

4.1. Introduction

4.2. Most active Molecular Diagnostics dealmakers

4.3. Most active Molecular Diagnostics partnering company profiles

 

Chapter 5 – Molecular Diagnostics contracts dealmaking directory

 

5.1. Introduction

5.2. Molecular Diagnostics contracts dealmaking directory

 

Chapter 6 – Molecular Diagnostics dealmaking by technology type

 

Appendices

 

Appendix 1 – Molecular Diagnostics deals by company A-Z

Appendix 2 – Molecular Diagnostics deals by stage of development

Appendix 3 – Molecular Diagnostics deals by deal type

Appendix 4 – Molecular Diagnostics deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Molecular Diagnostics partnering since 2015

Figure 2: Active Molecular Diagnostics dealmaking activity– 2015 to 2022

Figure 3: Molecular Diagnostics partnering by deal type since 2015

Figure 4: Molecular Diagnostics partnering by disease type since 2015

Figure 5: Molecular Diagnostics deals with a headline value

Figure 6: Molecular Diagnostics deals with an upfront value

Figure 7: Molecular Diagnostics deals with a milestone value

Figure 8: Molecular Diagnostics deals with a royalty rate value

Figure 9: Top Molecular Diagnostics deals by value since 2015

Figure 10: Most active Molecular Diagnostics dealmakers 2015 to 2022

Pricing options

 

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2bPrecise, 2cureX, 3D BioMed, 3PrimeDx, 4D Path, 10X Genomics, 14M Genomics, 23andMe, 221b Foundation, A*STAR Agency for Science, Technology and Research, Abbott Laboratories, Abbvie, Abcam, Abcodia, Abramson Cancer Center, Accelerate Diagnostics, Accelerate Technologies, Access BIO, AccuGenomics, AccuRef Diagnostics, AC Immune, Acumen Pharmaceuticals, Acupath Laboratories, Adaptive Biotechnologies, Adial Pharmaceuticals, Aditx Therapeutics, ADMA Biologics, Admera Health, ADS, Advanced Biological Laboratories, Advanced Cell Diagnostics, Advanced Cooling Therapy, Advanced Genomic Solutions, Advanced Medical German Company of Kuwait, ADx Healthcare, Aegea Biotechnologies, Aetna, Affymetrix, Age Labs, Agena Bioscience, Agendia, Agilent Technologies, Agios Pharmaceuticals, Air Force Research Laboratory, Akers Biosciences, Ako Med, Akonni Biosystems, Akoya Biosciences, Alamar Biosciences, Albertsons Companies, ALBOT Technologies, Aldeyra Therapeutics, Alibaba Health, Allele Biotechnology and Pharmaceuticals, Allelica, Alliance Global FZ, Alliance Global Group, Almac Diagnostics, Alnylam Pharmaceuticals, Alpha-Tec Systems, Alphazyme, Alverno Clinical Laboratories, Alzheimer's Drug Discovery Foundation, Alzheon, Amazon Web Services, Ambry Genetics, A Menarini Diagnostics, America's Choice Provider Network, Amgen, Amoy Diagnostics, Amplitech, Anavasi Diagnostics, AnchorDx, Angle, Angsana Molecular & Diagnostics, Anixa Biosciences, Annar Health Technologies, Anpac Bio-Medical Science, AnteoTech, Anthem Bluecross, Antisoma Therapeutics, Applied BioCode, Aptorum Group, Arbor Biosciences, ArcherDX, Ares Genetics, Ares Life Sciences, Ariosa Diagnostics, Arisan Therapeutics, Arizona State University, AroCell, Arrow Diagnostics, Ashion Analytics, ASPiRA Labs, Aspira Scientific, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, Asterand Bioscience, Asthma UK, AstraZeneca, Astute Medical, Asuragen, AsureQuality, ATGen Global, Athletigen, Atlas Antibodies, Atlas Genetics, Atlas Genomics, Atomo Diagnostics, Atrin Pharmaceuticals, Atrys Health, Autobio Diagnostics, AutoGenomics, Avacta, Avalon GloboCare, Avant Diagnostics, Avera Health, Avricore Health, Axella Research, AXIM Biotechnologies, Babson Diagnostics, Baebies, BASE10 Genetics, Bay Area Lyme Foundation, Bayer, Baylor Genetics, BBI Solutions, BC Neuroimmunology, BC Platforms, BD Biosciences, Beckman Coulter, Be Creative Lab, Becton Dickinson, Beijing Genomics Institute (BGI), Berg, Beroni Group, Berry Genomics, Berry Oncology, Bertech Diagnostics, Be The Match BioTherapies, BHR Pharma, Bill and Melinda Gates Foundation, BillionToOne, Bio-Me, Bio-Rad Laboratories, Bio-Techne, bioAffinity Technologies, BioAnalytical Systems, BIOASTER, Biocartis, Biocept, BioChain, BioCheck, Biodesix, Biodirection, BioDiscovery, Biodist, Biofidelity, BioGemex, Biognosys, BioGX, Biohealth Innovation, Biohit Healthcare, BioInvent, BioIQ, Biolidics, Biological Dynamics, BioMark Diagnostics, Biomedical Advanced Research and Development Authority, Biomeme, Biomerica, bioMerieux, Biomillenia, BioNano Genomics, BioNova Cientifica, BioReference Laboratories, Biosearch Technologies, BioSkryb, BioSure, Biotech-IgG, BioTheranostics, BioVaxys, Biovica, BKare Diagnostics, BL&H, Bluebee, Blue Cross Blue Shield Association, BlueCross BlueShield of Tennessee, Blueprint Genetics, Boehringer Ingelheim, Boreal Genomics, Bosch, BostonGene, Boston IVF, Bostwick Laboratories, Bpifrance, Brahms, Brandeis University, Breath Diagnostics, Brigham and Women's Hospital, Brigham Young University, Brik, Bristol-Myers Squibb, Broad Institute, Brotman-Baty Institute, Bruker, Burning Rock, BurstIQ, C2i Genomics, C2N Diagnostics, Calviri, Cambridge Enterprise, Cambridge Epigenetix, Cambridge Isotope Laboratories, Canabo Medical Clinics, Canadian Cancer Society, Canadian Institutes of Health Research, Cancer Genetics, Cancer Research Institute, Cancer Research UK, Canon U.S. Life Sciences, Caprion Proteomics, Capsulomics, CARB-X, Cardea Bio, Cardiff University, Cardinal Health, CareDx, CareFirst BlueCross BlueShield, Caris Life Sciences, Carpegen, Case Western Reserve University, CAS Medical Systems, Castle Biosciences, Catholic University Leuven, CDx Diagnostics, Celcuity, Celgene, Cellgen Diagnostics, Cell Guidance Systems, CellMax Life, Cellpath, Celmatix, Celsee, Celsius Therapeutics, Cenetron, Centers for Disease Control and Prevention, Centogene, Centre Leon Berard, Cepheid, Cerba HealthCare, Cerveau Technologies, Charcot-Marie-Tooth Association, Charles River Laboratories, CHDI Foundation, Chembio Diagnostics, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Orange County, Christian Doppler Research Association, Chronix Biomedical, Chubu University, Cicero Diagnostics, Cipla, Circulogene, Cirrus Dx, City of Hope, Clarity Pharmaceuticals, Clearbridge Biomedics, ClearLight Diagnostics, Cleveland Clinic, Cleveland Diagnostics, Clinical Genomics, Clinic for Special Children, CloudHealth Genomics, CLX Health, CND Life Sciences, Co-Diagnostics, Codexis, Coeptis Pharmaceuticals, Cofactor Genomics, Colorado Melanoma Foundation, Color Genomics, Columbia University, Companion Medical, Concert Genetics, Concile, Congenica, Contextual Genomics, COPAN, Copenhagen University Hospital, CoreBiome, Core Diagnostics India, Corgenix Medical, Coriell Life Sciences, Cornell University, Corona Diagnostics, Corvida Medical, COTA, Covance, CQuentia, Cradle Genomics, Creoptix, Crossbeta Biosciences, Crown Dental + Medical, CSI Laboratories, Cue Health, Cumming, Cure Forward, Cureleads, Curetis, Cynvenio, Cypher Genomics, Cypre, Cytiva, CytoLumina Technologies, Cytox, D-Eye, Dahui Biotech, Daktari Diagnostics, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, DarioHealth, Dartmouth-Hitchcock Medical Center, DarwinHealth, Daxor, DeciBio Consulting, Decipher Biosciences, deCODE Genetics, Deep Bio, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Definiens, Dell Medical School, Deltex Medical, Denali Therapeutics, Dendreon, Denso, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, DermTech, DestiNA Genomics, Devyser Diagnostics, DiaCarta, Diagen, Diagnoplex, Diagnostica Longwood, Diagnostic International Distribution, Diagnostic Oncology Contract Research Organization, DiamiR, DIAN Diagnostics, Diaprost, DiaSorin, DIAsource ImmunoAssays, Diaxonhit, DNA Link, DNAmito, Drawbridge Health, Duchenne UK, Duke University, DxTerity, DySIS Medical, E25Bio, Eastern Ontario Regional Laboratory Association, Eccrine Systems, EchelonDx, Edan Diagnostics, Edico Genome, EDP Biotech, EKF Diagnostics, Elevation Oncology, Eleven Biotherapeutics, Eli Lilly, Elucigene, Eluthia, Emerald Organic Growth, Emmes, Emory University, Empire Genomics, Empowered Diagnostics, Emulate, Endotronix, Enterome Bioscience, Enzyre, Enzyvant Science, EpicGenetics, Epicore Biosystems, Epic Sciences, Epimune Diagnostics, Epiphany Dermatology, Epivax, Erasmus University Medical Center, Erisyon, ESSA Pharma, Ethos Laboratories, Ethos Research & Development, Ethos Veterinary Health, Eureka Eurostars, EuroClone, Eurofins Scientific, European Commission, European Health Centre Innovation, European Organization for Research and Treatment of Cancer, European Union, Everything Genetic, Evexia Diagnostics, Evogen, Evotec, Exact Sciences, Exagen Diagnostics, Exosome, Exosome Diagnostics, Exosome Sciences, Expedeon, Expesicor, ExSeed, F-Star Therapeutics, Factorial Diagnostics, Falco, Fast-Track Diagnostics, Feinstein Institute for Medical Research, FetoLumina Technologies, Fianostics, Fio, First Genetics JCS, Five Prime Therapeutics, Flagship Biosciences, Flatiron Health, Florida International University, FlowMetric, Fluoresentric, Fluxion Biosciences, FLX Bio, FNApath, Fondation Cancer, Fondatioun Kriibskrank Kanner, Forsitech, Fortelinea Software Systems, Fortified Provider Network, Fosun Pharmaceutical, Foundation for the National Institutes of Health (FNIH), Foundation Medicine, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Freenome, Fudan University, Fujirebio Diagnostics, Fulgent Genetics, Fundacion Progreso y Salud, Fusion Genomics, Galectin Therapeutics, GE Healthcare, Gemelli Biotech, Gemini Therapeutics, Genclis, Gencove, Genecast, GeneCentric Therapeutics, GeneDX, GeneInsight, GeneNews, Genentech, GenePOC, GeneThera, Genetic Analysis, Genetic Technologies, Genetron Health, Genewiz, Genfit, Genoma, Genome Canada, GenomeDx, Genome Institute of Singapore, Genome Prairie, GenomeSmart, Genomic Health, Genomics England, Genomic Testing Cooperative, Genomind, Genomoncology, Genosity, GenScript Biotech, Genticel, George Mason University, Georgia Institute of Technology, German Federal Ministry of Education and Research, Gestalt Diagnostics, Gibraltar Brothers and Associates, Ginkgo BioWorks, GI OnDEMAND, GlaxoSmithKline, GLG Pharma, Global Cancer Diagnostics, Globavir Biosciences, Gloval Specimen Solutions, GNS Healthcare, GNYHA Services, Goffin Molecular Technologies, Good Start Genetics, Government of Canada, Grail, Great Basin Scientific, Greater New York Hospital Association, Great Lakes Medical Laboratory, Group K Diagnostics, Grupo Ferrer, GSK Consumer Healthcare, Guardant Health, Gyros Protein Technologies, Hackensack Meridian Health, HalioDx, HALO Diagnostics, Harvard Medical School, Harvard University, HEALTH Biomed, Heat Biologics, Hebrew University of Jerusalem, Helio Health, Helix, Helix2, Helomics, HemaTone, Hemex Health, HemoShear, Henry M. Jackson Foundation, Henry Schein, Hereditary Neuropathy Foundation, Hesperos, Highmark Blue Shield, HiMedia Laboratories, Hitachi High-Technologies Corporation, HMicro, Hoag Memorial Hospital Presbyterian, Horizon 2020, Horizon Discovery, Hospital of University of Strasbourg, HTG Molecular Diagnostics, Hubrecht Organoid Technology, Hudson Robotics, Humana, Human Longevity, Hummingbird Bioscience, Hummingbird Diagnostics, hVIVO, Hy Laboratories, I-MED Pharma, Ibex Medical Analytics, iBIO Institute’s PROPEL Center, IBL America, Icahn School of Medicine at Mount Sinai, Ichor Blood Services, Idaho Urologic Institute, IDbyDNA, Idengene, IDEXX Laboratories, IES Diagnostics, Illumina, ImageMover, ImaginAb, Imaware, Imec, Imegen, ImmunArray, Immunexpress, ImmunID Technologies, ImmunoCellular Therapeutics, ImmunoPrecise Antibodies, Immunovia, Imperial College London, IncellDx, InDevR, Indica Labs, Indivumed, Infinity BiologiX, Inflammatix, Informed Data Systems, Inhibrx, Inivata, Innovate UK, Innovation Skane, Inova Health System, Inova Labs, Inova Translational Medicine Institute, Inserm Transfert, Insight Genetics, Institut Català d'Oncologia, Institut Curie, Institute for Bioscience and Biotechnology Research, Institute for Genome Statistics and Bioinformatics, Institute for Systems Biology, Institute of Biophysics, Institute of Cancer Research, Institute of Human Genetics, Institute of Organic Chemistry and Biochemistry, Institut Gustave Roussy, Instituto Diagnostico Varelli, Institut Paoli-Calmettes, Institut Pasteur, IntegraGen, Integrated Biobank of Luxembourg, Integrated Diagnostics, Integrated Micro-Chromatography Systems, Intelligence Advanced Research Projects Activity (IARPA), Interlab INTERAUTOMATIKA UAB, Interleukin Genetics, Intermountain Healthcare, International Isotopes, Interpace Diagnostics, InterSystems, Invitae, InVivoScribe, ION Solutions, IP Biotech, IPS Genomix, iRemedy Healthcare Companies, Ironwood Pharmaceuticals, IRX Therapeutics, IsoPlexis, ISOThrive, Itus, IviGen, Janssen-Cilag, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Agency for Medical Research and Development, Jefferson Healthcare, Jeffrey Modell Foundation, Jiangsu Chia Tai Tianqing Pharmaceutical, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wayne Cancer Institute, Kaiser Foundation Research Institute, Kaiser Permanente, Kantaro Biosciences, Karolinska Institute, Karolinska University Hospital, KDx Diagnostics, KEW, Kim & Friends, Kindstar Globalgene Technology, Kiromic Biopharma, Kite Pharma, Knight Cancer Institute, Konica Minolta Precision Medicine, KromaTiD, Krystal Biotech, Kurabo, Kura Oncology, Labcyte, Lab Genomics, Laboratory Corporation of America, La Jolla Institute for Allergy & Immunology, LamdaGen, Lantheus Holding, Leap Therapeutics, Lee Moffitt Cancer Center, Leica Biosystems, Leicester University, Leinco Technologies, Leonie Hill Capital, LEO Pharma, Les Laboratoires Servier, LexaGene, LGC, LifeLabs Medical Laboratory Services, Life Raft Group, LifeX Ventures, Li Ka Shing Foundation, LineaRx, Liverpool School of Tropical Medicine, LogicInk, Longhorn Vaccines and Diagnostics, Lorna Linda University, Lucence, Lucid Diagnostics, Luminex, LuminUltra, LumiraDx, Lunatus, Lund University, Lung Cancer Alliance, Lupus Research Alliance, Macrogen, Madison Core Laboratories, Magellan Healthcare, Magenta Therapeutics, Mammoth Biosciences, Manhattan Scientifics, Mannin Research, Massachusetts General Hospital, Massachusetts Institute of Technology, Maverix Biomics, Mayo Clinic, MBio Diagnostics, McMaster University, MD Anderson Cancer Center, MD Biosciences, MDL Information Systems, MDNA Life Sciences, MDxHealth, med fusion, MEDIAN Technologies, Medical University of Graz, Medical University of South Carolina, Medical University of Vienna, MediCare International, MediSapiens, Medline Industries, MedMira, MedQuest, Memorial Sloan Kettering Cancer Center, Menon Biosensors, Merck and Co, Merck KGaA, Merck Serono, Meridian Bioscience, Mesa Biotech, Metabiomics, Metabolomic Diagnostics, Metabolon, Metafora Biosystems, Metamark Genetics, MetaStat, MGI Pharma, Michael J Fox Foundation, Michelson Center, Microbix Biosystems, MicroConstants, Micromedic Technologies, Microsoft, Mikrogen, Mimetas, MiNDERA, MindX Sciences, Minomic, MIODx, Miraca Life Sciences, Miragen Therapeutics, miR Scientific, MiRXES, MIT, MiTest Health, Mobidiag, MobileODT, Molbio Diagnostics, Moldionics, Molecular Health, Molecular Matrix, MolecularMD, Molecular Stethoscope, Molecular Targeting Technologies, Molecular Testing Labs, Molecular You, MolGen, Molnlycke Health Care, Mologic, Moores Cancer Center, Mount Sinai Health System, mProbe Laboratories, MRIGlobal, MRM Proteomics, Multi G, Multiple Myeloma Research Foundation, Multiplex Genomics, Muscular Dystrophy Association, Myelopro Diagnostics and Research, My Gene Counsel, Mylab Discovery Solutions, Myriad Genetics, Myriad RBM, N-of-One, NanoMab Technology, Nanommune, NanoString Technologies, NantHealth, Natera, National Cancer Centre Singapore, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Healthcare Services (NHS), National Institute for Public Health and the Environment, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Kidney Registry, National Science Foundation, Natural Sciences and Engineering Research Council of Canada, Navidea Biopharmaceuticals, NEC, Nektar Therapeutics, NeoDynamics, Neogen, Neogenomics, NEO New Oncology, Nestle Health Science, NetScientific, NeuMoDx Molecular, New England Biolabs, New Horizon Health, New York Genome Center (NYGC), New York University, Next Gen Diagnostics, NextGxDx, NM Genomix, Nonagen Bioscience, Norgine, NorthBay Healthcare, Northwestern University, Norwegian Institute of Public Health, Norwegian Research Council, Notable Labs, Novartis, Novation, NovellusDx, Novigenix, Noviscend, Novogene, NOWDiagnostics, Nucleai, Nucleix, numares, NuProbe, NX Prenatal, Ohio State University, Oklahoma Medical Research Foundation, Oligomerix, OmniSeq, Oncgnostics, Oncimmune, OncoCyte, OncoDNA, OncoGenesis, OncoNano Medicine, Oncotest, One BioMed, One Lambda, Ono Pharmaceutical, Ontario Institute for Cancer Research, Ontera, Opentrons Labworks, OpGen, OPKO Health, Orebro University, Oregon Health Sciences University, ORIG3N, Origin Biosciences, Ortho-Clinical Diagnostics, OSANG Healthcare, Oslo University Hospital, Oswaldo Cruz Foundation (Fiocruz), Ovarian Cancer Institute, OvuSense, Owlstone Medical, Oxford Biodynamics, Oxford Immunotec, Pacific Biosciences, Paige, Pain Therapeutics, PapGene, Paradigm, Paralax Life Science Group, Parent Project Muscular Dystrophy, Parexel, Parkway Clinical Laboratories, Partners HealthCare, Passage Bio, PathGroup, Pathway Diagnostics, Pathway OME, Patia, Paul G Allen Family Foundation, PAVmed, Pax Neuroscience, PBL Assay Science, Pennsylvania State University, PeptiDream, Peregrine Market Access, PerkinElmer, Personal Genome Diagnostics, Personalis, Personalized Medicine Initiative (PMI), PersonalizeDx, Perspectum Diagnostics, Perthera, PetDx, Pfizer, Pfizer Canada, Pharmacological research Institute Mario Negri, Phase Genomics, Phenomix, Phi Life Sciences, Philips, Phillips-Medisize, Phoenix Molecular Designs, Phosphorus Genomics, Physician’s Choice Laboratory Services, PierianDx, Pillar Biosciences, Planet Innovation, Plexision, Point32Health, Population Genetics Technologies, PPD, Precipio Diagnostics, Precision Diabetes, Precision for Medicine, Precision Pathology Services, Predicine, PredictImmune, Predictive Health Diagnostics, Predictive Technology Group, PrediLife, PreludeDx, Premaitha Health, Premas Life Sciences, Premier Health Group, Premier Inc, Prenetics, Prenosis, Preora Diagnostics, Prescient Medical, Pressure BioSciences, Prevencio, PreventionGenetics, Prime Health Services, Primetech, ProciseDx, Progenetics, Progentec Diagnostics, PrognomIQ, ProMIS Neurosciences, Propper Manufacturing, Protagen, Protea Biosciences, Protean BioDiagnostics, ProterixBio, Provider Network of America, Provista Diagnostics, Psyche Systems, PTC Therapeutics, Puerto Rico Government, Puma Biotechnology, Pure MHC, PWNHealth, Pyrobett, Q2 Solutions, Qiagen, Quadrant Biosciences, Quanterix, QuantumDx, Quebec Heart and Lung Institute, Queensland University of Technology, Quest Diagnostics, Quidel, QuiO Technologies, Quotient, Qura Therapeutics, Radboud University Nijmegen Medical Centre, Rady Children's Institute for Genomic Medicine, Ragon Institute, Rainbow Genomics, Rapid Micro Biosystems, Rarecells, Realm IDx, RenalytixAI, Renegade Bio, Renji Hospital, Renovar, Repertoire Genesis, Reproductive Health Science, Research Center for Molecular Medicine of the Austrian Academy of Sciences, ResearchDx, Resolution Bioscience, Reveal Genomics, rEVO Biologics, RevoluGen, Rheonix, Rice University, Righton, Riken Genesis, RNA Disease Diagnostics, Roche, Roche Diagnostics, Roche Molecular Systems, Rokline Health Concepts, Rosetta Genomics, Roswell Biotechnologies, Roswell Park Cancer Institute, Royal Marsden Hospital, Royal Philips Electronics, RTI International, SAGA Diagnostics, Sanford Guide, Sanofi, Saol Therapeutics, Sarah Cannon Research Institute, Sarepta Therapeutics, Sayre Therapeutics, Scienion, Sciex, Scipher Medicine, SC Liver Research Consortium (SCLRC), Seattle Children's Hospital, Sebela Pharmaceuticals, Seegene, Seer, Sekisui Diagnostics, Sekris Biomedical, Selexis, Sema4, SEngine Precision Medicine, Senova Systems, Sense Biodetection, Sentinel Diagnostics, SenzaGen, Sequenom, Seracare Life Sciences, Serametrix, Shanghai Fosun Long March Medical Science, Sherlock Biosciences, Shire Human Genetic Therapies, Shire Laboratories, Siemens Healthcare, Siemens Healthineers, Signal Genetics, Silicon Biosystems, Singlera Genomics, Singulex, Sino Biological, Sintact Medical Systems, Siolta Therapeutics, Skane University Hospital, SkylineDX, Skyline Medical, Skysong Innovations, Sonic Healthcare, Sonora Quest Laboratories, Sony DADC, Sophia Genetics, Sorgente, Sorrento Therapeutics, Source Molecular, SouthGenetics, Spectrum Health, Spectrum Solutions, SpeeDx, SpePharm, Spesana, SphereDX, Sphingotec, SQI Diagnostics, SRI International, St. Jude Children's Research Hospital, STADA Arzneimittel, Standard Capital, Standard Process, Stanford University, Stanford University School of Medicine, State of New Jersey, StatSure Diagnostic Systems, StemCyte, St Georges University of London, Strain Genie, Stratify Genomics, Stratose, Streck Laboratories, Sunnybrook Research Institute, Svar Life Science, SweLife, Swift Biosciences, SYGNIS Pharma, Symbiotix Biotherapies, Synexa Life Sciences, Syngene International, SynGenis, Synlab, Syracuse University, Sysmex, Sysmex Inostics, Systec, T-Cure Bioscience, T2 Biosystems, Tabula Rasa HealthCare, TaiRx, TaiRx US, Take2, Takeda Pharmaceutical, Tangen Biosciences, Taysha Gene Therapies, Tebu-Bio, Tecan, Tempus, Tesis Biosciences, Texas A&M University, The Binding Site, The Parker Institute For Cancer Immunotherapy, Theralink Technologies, Thermo Fisher Scientific, ThermoGenesis, Thomas Jefferson University, Three Rivers Provider Network, TNK Therapeutics, Todos Medical, Tokai University, Toronto Innovation Acceleration Partners, Tor Vergata University Hospital, Toyohashi University of Technology, Transcriptome Sciences, Transgenomic, Translational Drug Development, Translational Software, Transplant Genomics, TrovaGene, True Diagnostics, TScan Therapeutics, TTP Group, Tufts Medical Center, Turgut Ilaclari, Twist Bioscience, Tymora Analytical Operations, uBiome, Ubiquitome, UgenTec, UK Government, UK NEQAS, Uman Diagnostics, Una Health, Unified Women's Clinical Research, Uniformed Services University of the Health Sciences, Unilabs, UniQuest, UnitedHealthcare, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University Hospital Bispebjerg, University Hospital of Leuven, University Hospitals Case Medical Center, University Medical Center Hamburg-Eppendorf, University of Antwerp, University of Birmingham, University of Bonn, University of Bristol, University of British Columbia, University of California, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cincinnati, University of Colorado Denver, University of Greifswald, University of Houston, University of Leeds, University of Manchester, University of Maryland, Baltimore County, University of Maryland Baltimore, University of Melbourne, University of Miami, University of Michigan, University of Minnesota, University of North Carolina, University of Oxford, University of Pennsylvania, University of Rochester, University of Rostock, University of Southampton, University of Texas Medical Branch, University of Texas Southwestern Medical Center, University of Tubingen, University of Washington, UPMC, Urology Centers of Alabama, Urology San Antonio, USC Norris Comprehensive Cancer Center, US Department of Commerce, US Government, US Oncology, Vanderbilt University, Vantari Genetics, Varian Medical Systems, Vela Diagnostics, Ventana Medical Systems, Veracyte, Veravas, VerdePharmHealth, Veritas Genetics, Vermillion, VHA, Viatar CTC Solutions, VIB, Victoria University, Vigilant Biosciences, Vikor Scientific, ViraCor Laboratories, Viravaxx, Vir Biotechnology, Vitatex, ViveBio, Vizient, VolitionRX, VyGen-Bio, Waseda University, Webb Diagnostic Technologies, Weihai Weigao Medical Devices, Weill Cornell Medical College, Welgene Biotech, Wellcome Trust, WellDyne, Wellgistics, Wuxi Apptec Laboratory Services, WuXi Biologics, WuXi NextCODE Genomics, Wyss Institute, X4 Pharmaceuticals, XboXLab, XCR Diagnostics, Xylonix, Yale University, Yemaachi Biotech, Yesse Technologies, Yitu Medical, Ymir Genomics, YourRad, ZenTech, Zenyaku Kogyo, Zomedica, zPREDICTA, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.